Oct. 20 at 10:02 AM
                            
WATCHLIST OCT 20 2025
$NVO FDA Approves Novo Nordisk's Oral Semaglutide For Cardiovascular Risk Reduction In Adults With Type 2 Diabetes Who Are At High Risk, Including Those Who Have Not Had A Prior CV Event
$SNY AlphaMedix Shows Durable, Clinically Meaningful Responses In Advanced GEP-NETs, Meeting All Primary Endpoints In Phase 2 Study
$IOBT IO Biotech Phase 3: Cylembio Plus KEYTRUDA Extends Median PFS To 19.4 Months In First-Line Advanced Melanoma, Showing Clinically Meaningful Improvement Despite Narrow Miss On Statistical Significance
$PHAR Pharming Group To Present 12 Abstracts At ACAAI 2025 Highlighting New Data For RUCONEST And Joenja Across Rare Diseases
$STM STMicroelectronics Introduces Four New 5MP BrightSense Image Sensors For Industrial Automation, Security, And Smart Retail Applications